Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
MelanomaNon Small Cell Lung Cancer15 moreAI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
Head and Neck CancerHead and Neck Carcinoma2 moreThe purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Pancreatic Ductal Adenocarcinoma (PDAC)Squamous Cell Carcinoma of Head and Neck5 moreThis is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable...
Head and Neck Squamous Cell CarcinomasA prospective, randomized, open-label, multicenter Phase 3 trial designed to compare the safety and efficacy of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable head and neck squamous cell carcinoma.
Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell CarcinomaNeoadjuvant ChemotherapyThe objective of research is to evaluate the efficacy and safety of treprizumab injection combined with AP regimen in the treatment of resectable locally advanced head and neck squamous cell carcinoma.122 patients were randomly divided into two groups: the test group (treprizumab injection combined with AP protocol) and the control group (TP protocol); The patients in both groups were treated with three cycles of induction therapy. After the induction therapy, the patients were evaluated and followed up with surgery.
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the...
Advanced Head and Neck Squamous Cell CarcinomaAdvanced Breast Cancer1 moreThis Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab. Additionally, the study will assess anti-tumor effects of CyPep-1 on injected lesions and non-injected target lesions identified at baseline, as well as local and systemic immunological effects of CyPep-1 in combination with pembrolizumab.
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Head and Neck Squamous Cell CarcinomaOpen-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy and safety combined pembrolizumab and lenvatinib as maintenance therapy after definitive radiochemotherapy of locally advanced head and neck squamous cell carcinoma (HNSCC).
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC...
Head and Neck Squamous Cell CarcinomaA phase Ⅱ open label multi-cencter clinical trail to evaluate the efficacy and safety of pembrolizumab combined with low-dose PF (cisplatin + 5-fluorouracil) in the neoadjuvant treatment of locally advanced head and neck squamous cell carcinoma
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients...
CarcinomaRecurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaThis is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in...
Head and Neck CancerThe purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).